EL7.AI
StocksMedium•27 October 2026•
2 min read

Mankind Pharma operating revenue rises 17.3% to 43.38 billion rupees in September quarter

Key Facts

1Operating revenue rose 17.3% to 43.38 billion rupees in the September 2026 quarter.
2Domestic revenue, excluding consumer healthcare, rose 16% to 34.28 billion rupees in the September 2026 quarter.
3The cardiac segment grew 19% and the anti-diabetes business rose 16% in the September 2026 quarter.
4The company's stock rose 4.5% on October 26, 2026, after the results announcement.

Mankind Pharma's operating revenue rose 17.3% to 43.38 billion rupees in the September 2026 quarter, according to a Reuters report published on October 26. Revenue growth came alongside increased demand for chronic medicines, the report said, as the company announced its second-quarter results on the same day. Domestic business revenue, excluding consumer healthcare, rose 16% to 34.28 billion rupees. This indicates that the domestic market was a key source of expansion during the quarter. After the results announcement, the company's stock rose 4.5% on Monday, October 26, according to Moneycontrol coverage.

Reuters attributed growth in the domestic formulations business to steady demand for chronic treatments, including diabetes medicines and cardiovascular therapies. The cardiac segment grew 19% in the September 2026 quarter, while the anti-diabetes business rose 16%. These figures detail the demand drivers that contributed to domestic revenue growth, rather than offering only a general description of the company's performance. They also highlight the contribution of chronic therapeutic areas to quarterly performance, the report said. The available information did not specify each segment's contribution to total revenue.

The figures showed broader revenue growth across domestic operations, with domestic revenue excluding consumer healthcare reaching 34.28 billion rupees, up 16% from the year-earlier period, according to Reuters. Overall operating revenue rose 17.3% to 43.38 billion rupees. This places domestic market growth in the context of the company's overall revenue performance during the quarter. The comparison between the two rates shows that total operating revenue grew faster than the domestic revenue figure cited in the report. The source did not provide a comparable breakdown for the other revenue components.

In the market, Mankind Pharma's stock rose 4.5% on Monday, October 26, after the results announcement, according to Moneycontrol. The timing places the move on the day of the announcement itself, rather than in trading on October 27. The company announced its second-quarter results on October 26, 2026, according to NDTV Profit. The information provided does not support a comparison with analyst estimates, so the results cannot be described as having exceeded expectations. The documented stock gain was 4.5%, not the higher percentage cited in the previous draft.